Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Diacerein - TWi Biotechnology/Castle Creek Pharmaceuticals

Next Previous
Drug Profile

Diacerein - TWi Biotechnology/Castle Creek Pharmaceuticals

Alternative Names: AC-201; AC-201 Controlled release tablet; AC-201 CR; AC-203; CCP 020

Latest Information Update: 23 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TWi Biotechnology; TWi Pharmaceuticals
  • Developer Castle Creek Pharmaceuticals; TWi Biotechnology
  • Class Anthraquinones; Anti-inflammatories; Antihyperglycaemics; Antirheumatics; Skin disorder therapies; Small molecules
  • Mechanism of Action Caspase 1 inhibitors; Interleukin 1 beta inhibitors; NLRP3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa
  • New Molecular Entity No

Highest Development Phases

  • Phase III Epidermolysis bullosa
  • Phase II Bullous pemphigoid; Gout; Joint disorders; Type 2 diabetes mellitus
  • Discontinued Diabetic nephropathies

Most Recent Events

  • 07 Feb 2024 Phase-II/III clinical trials in Epidermolysis bullosa (In infants, In children, In adolescents, In adults, In the elderly) in Taiwan, Australia (Topical) (NCT06073132)
  • 13 Oct 2023 TWi Biotechnology plans a phase II/III open-label extension trial in Epidermolysis bullosa (In infants, In children, In adolescents, In adults, In the elderly) (Topical, Ointment) (NCT06073132)
  • 27 Sep 2022 No development reported - Phase-II for Epidermolysis bullosa (In adolescents, In children, In the elderly, In infants, In adults) in Austria, Netherlands, Germany, France, United Kingdom, USA (Topical) (Castle Creek Pharmaceuticals pipeline; September 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top